Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1gobymedsglp-1telehealthpricing

Telehealth provider GobyMeds faces scrutiny over dose-based GLP-1 pricing

Consumer-facing review examines whether the GLP-1 seller increases monthly charges as patients titrate to higher doses.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 23:47 ETSource: PlexusDx

The wire

  1. 01A consumer review assesses whether GobyMeds raises GLP-1 prices as patient doses escalate.
  2. 02Dose-tiered pricing affects affordability for patients on long-term GLP-1 therapy.
  3. 03No independent verification of the provider's pricing structure is presented.

From the source

Does GobyMeds Raise GLP-1 Prices When Your Dose Increases? — 2026

Read at news.google.com